Vor Biopharma Inc.
Organization details
- Legal name
- Vor Biopharma Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- VOR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001817229
- EIN
- 81-1591163
Board of directors
-
Alexander Cumbo · DirectorSince 2025
-
Andrew David Levin · DirectorSince 2025
-
Daniella Beckman · DirectorSince 2023
-
David Charles Lubner · DirectorSince 2023
-
David Zaccardelli · DirectorSince 2026
-
Erez Kalir · DirectorSince 2025
-
Fouad Namouni · DirectorSince 2024
-
Jean-Paul Kress · Director · CEO and ChairmanSince 2025
-
Joshua Resnick · DirectorSince 2023
-
Matthew R. Patterson · DirectorSince 2023
-
Michel Detheux · DirectorSince 2025
- Since 2023
- Since 2023
-
Robert Ang · Director · PRESIDENT AND CEOSince 2023
-
Sarah Burgess Reed · DirectorSince 2025
-
Sven Ante Lundberg · DirectorSince 2023
-
Wouter Joustra · DirectorSince 2025
Chief executives
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.8%
-
99.5%
Board connections
11 of this board's directors also sit on 35 other boards. 35 are in the same sector.
-
Climb Bio Inc. Same sectorvia Alexander Cumbo, Andrew David Levin, Peter Kolchinsky and Rajeev M. Shah
-
Jade Biosciences Inc. Same sectorvia Joshua Resnick, Peter Kolchinsky and Rajeev M. Shah
-
PepGen Inc. Same sectorvia Joshua Resnick, Peter Kolchinsky and Rajeev M. Shah
-
Sionna Therapeutics Inc. Same sectorvia Joshua Resnick, Peter Kolchinsky and Rajeev M. Shah
-
Solid Biosciences Inc. Same sectorvia Alexander Cumbo, Peter Kolchinsky and Rajeev M. Shah
-
ARS Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Acrivon Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Acumen Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Artiva Biotherapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bambusa Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bicara Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Black Diamond Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Evommune Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Freenome Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Hemab Therapeutics Holdings Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Janux Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
LENZ Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Mineralys Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Nkarta Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Parabilis Medicines Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Q32 Bio Inc. Same sectorvia Matthew R. Patterson and Sven Ante Lundberg
-
Septerna Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
SpyGlass Pharma Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Tyra Biosciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Wave Life Sciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Werewolf Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Braveheart Bio Inc. Same sectorvia David Charles Lubner
-
Crescent Biopharma Inc. Same sectorvia David Charles Lubner
-
Dyne Therapeutics Inc. Same sectorvia David Charles Lubner
-
NewAmsterdam Pharma Company N.V. Same sectorvia Wouter Joustra
-
SAB Biotherapeutics Inc. Same sectorvia David Zaccardelli
-
Stoke Therapeutics Inc. Same sectorvia Alexander Cumbo
-
Upstream Bio Inc. Same sectorvia Daniella Beckman
-
Yarrow Bioscience Inc. Same sectorvia Sven Ante Lundberg
-
enGene Therapeutics Inc. Same sectorvia Wouter Joustra
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $49,419,525
- 16 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sokolove Jeremy Brett Officer (Chief Medical Officer) | Shares withheld for tax | −1,917 | $19.25 | $36,902 |
| Oct 2, 2026 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Option exercise | +500 | $12.80 | $6,400 |
| Aug 24, 2026 | RA Capital Healthcare Fund LP 10% owner | Option exercise | +1,500 | $3.74 | $5,610 |
| Jul 16, 2026 | Rajeev M. Shah 10% owner | In-the-money exercise | +2,100,000 | — | — |
| Jul 16, 2026 | Rajeev M. Shah 10% owner | Open-market sale | −213 | $19.75 | $4,207 |
| Apr 22, 2026 | Rajeev M. Shah Director, 10% owner | Open-market sale | −165,150 | $15.77 | $2,604,416 |
| Apr 20, 2026 | RA CAPITAL MANAGEMENT, L.P. Director, 10% owner | Open-market sale | −171,963 | $15.77 | $2,711,857 |
| Apr 17, 2026 | RA CAPITAL MANAGEMENT, L.P. Director, 10% owner | Open-market sale | −458,411 | $16.28 | $7,462,931 |
| Apr 15, 2026 | RA CAPITAL MANAGEMENT, L.P. Director, 10% owner | Open-market sale | −53,644 | $16.01 | $858,840 |
| Apr 14, 2026 | RA CAPITAL MANAGEMENT, L.P. Director, 10% owner | Open-market sale | −153,735 | $15.97 | $2,455,148 |
| Apr 13, 2026 | RA CAPITAL MANAGEMENT, L.P. Director, 10% owner | Open-market sale | −530,610 | $16.15 | $8,569,352 |
| Apr 10, 2026 | Rajeev M. Shah Director, 10% owner | Open-market sale | −828 | $15.75 | $13,041 |
| Apr 9, 2026 | Rajeev M. Shah Director, 10% owner | Open-market sale | −135,201 | $16.59 | $2,242,985 |
| Apr 8, 2026 | Rajeev M. Shah Director, 10% owner | Open-market sale | −353,242 | $16.32 | $5,764,909 |
| Apr 8, 2026 | Rajeev M. Shah Director, 10% owner | Open-market sale | −130,862 | $16.91 | $2,212,876 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Vor Biopharma Inc.
Who is the CEO of Vor Biopharma Inc.?
Jean-Paul Kress has been Vor Biopharma Inc.'s CEO and Chairman since June 2025.
How many directors are on Vor Biopharma Inc.'s board?
Vor Biopharma Inc.'s board has 17 directors: Alexander Cumbo, Andrew David Levin, Daniella Beckman, David Charles Lubner, David Zaccardelli, Erez Kalir, Fouad Namouni, Jean-Paul Kress, Joshua Resnick, Matthew R. Patterson and 7 others.
Are Vor Biopharma Inc. insiders buying or selling shares?
Over the last 12 months, Vor Biopharma Inc. insiders made no open-market purchases and sold $49.4 million of shares in 16 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="vor-biopharma-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.